Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

Contact
Request a demo
Request data updates
Add a company

Research

Companies
Investors
People

aVenture

Sitemap
Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage

Loading

Loading

Ed Mathers

AddedMar 31, 2024

UpdatedMay 31, 2026

Ed Mathers

Ed Mathers

Board Member, Senti Biosciences

Ed Mathers's Career

Senti Biosciences

Senti Biosciences

South San Francisco, CA, US

Board Member· Board

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals

Boston, MA, US

Board Member· Board

Mirum Pharmaceuticals

Mirum Pharmaceuticals

Foster City, CA, US

Board Member· Board

Envisia Therapeutics

Envisia Therapeutics

Morrisville, NC, US

Board Member· Board

MBX Biosciences

MBX Biosciences

Carmel, IN, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Ed Mathers's Career

Senti Biosciences

Senti Biosciences

Public$215.9M1222016South San Francisco, CA, US

Board Member· Board

Recent news

Latest News and Press ReleasesNews · 2024

Senti Biosciences plans holding company reorganizationNews · 2024

Senti Biosciences Holdings (Nasdaq:SNTI) - Stock AnalysisNews · 2024

Leadership at Senti Biosciences

Wilson WongCo-Founder

Laurent FischerBoard Member

Omid FarokhzadBoard Member

Philip LeeCo-Founder

Jim CollinsCo-Founder

Similar to Senti Biosciences

HubSpotCambridge, MA, USest. 2006HubSpotCambridge, MA, US · est. 2006

HubSpot, Inc.: A cloud-based CRM platform providing integrated tools for adaptable business operations.

Public · $100.5M7.4k

SalesforceSan Francisco, CA, USCRM, Softwareest. 1999SalesforceSan Francisco, CA, US · est. 1999

Salesforce provides cloud CRM and AI enterprise software for sales, service, and marketing teams.

Public · $65.4M70.8k

Think BioscienceBoulder, CO, USMedicinesest. 2019Think BioscienceBoulder, CO, US · est. 2019

Think Bioscience innovates synthetic biology, designing superior medicines using living systems.

Seed · $17.3M26

Senda BiosciencesCambridge, MA, USMedicinesest. 2017Senda BiosciencesCambridge, MA, US · est. 2017

Senda: Innovatively harnessing molecular interactions for advanced medicine development.

Series C · $309M80

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals

Public$895.5M1772010Boston, MA, US

Board Member· Board

Leadership at Rhythm Pharmaceuticals

Jennifer GoodBoard Member

Christophe JeanBoard Member

Bart HendersonCo-Founder

David P MeekerBoard Member

Elizabeth StonerCo-Founder

Mirum Pharmaceuticals

Mirum Pharmaceuticals

Public$497M1962018Foster City, CA, US

Board Member· Board

Leadership at Mirum Pharmaceuticals

Laura BregeBoard Member

Tiba AynechiBoard Member

Mike GreyBoard Member

Niall O'DonnellBoard Member

Chris PeetzBoard Member

Jonathan LeffBoard Member

Similar to Mirum Pharmaceuticals

Intercept PharmaceuticalsNew York City, NY, USPharmaceuticalsest. 2002Intercept PharmaceuticalsNew York City, NY, US · est. 2002

Intercept Pharmaceuticals: An American biopharma firm specializing in synthetic bile acid analogs for chronic liver diseases.

Public · $970M341

Mirata PharmaceuticalsPlymouth Meeting, PA, USPain Relief, Pharmaceuticalsest. 2017Mirata PharmaceuticalsPlymouth Meeting, PA, US · est. 2017

Mirata Pharmaceuticals: Innovating powerful, opioid-based pain relief solutions for patients and physicians.

Series A · $11M5

Catalyst PharmaceuticalsCoral Gables, FL, USPharmaceuticals, Therapiesest. 2002Catalyst PharmaceuticalsCoral Gables, FL, US · est. 2002

Catalyst Pharmaceuticals: A US-based biopharmaceutical firm developing therapies for debilitating diseases.

Public · $273.9M76

Bayer PharmaceuticalsBerlin, Berlin, DEDrugs, Pharmaceuticalsest. 2003Bayer PharmaceuticalsBerlin, Berlin, DE · est. 2003

Bayer Pharmaceuticals: A global enterprise specializing in biochemical research and drug manufacturing since 2008.

Envisia Therapeutics

Envisia Therapeutics

Acquired$46.1M02013Morrisville, NC, US

Board Member· Board

Leadership at Envisia Therapeutics

Ben YerxaFounder

Adrienne GravesBoard Member

Gary M PhillipsBoard Member

William E YelleBoard Member

Steve BlochBoard Member

Similar to Envisia Therapeutics

VisioxTarrytown, NY, USTherapeuticsest. 2022VisioxTarrytown, NY, US · est. 2022

Visiox: A privately-funded biopharmaceutical firm innovating new treatments for prevalent ophthalmic diseases.

EyeCyteLos Angeles, CA, USTherapeuticsest. 2005EyeCyteLos Angeles, CA, US · est. 2005

EyeCyte: Developing novel therapeutics for neovascular and degenerative retinal diseases.

Series A · $3M5

Imagen BiotechNew York City, NY, USTherapeuticsest. 2011Imagen BiotechNew York City, NY, US · est. 2011

Imagen Biotech: Pioneering solutions for blinding diseases through innovative therapeutics.

Series A · $40M30

Nexis VisionMenlo Park, CA, USEye Solutionsest. 2007Nexis VisionMenlo Park, CA, US · est. 2007

Innovative biotech creating eye solutions for surgery and diseases.

Pre-Seed · $34.8M6

MBX Biosciences

MBX Biosciences

Series B$174.9M332019Carmel, IN, US

Board Member· Board

Leadership at MBX Biosciences

Patrick HeronBoard Member

Timothy KnickerbockerFounder

Kent HawrylukCEO

Carl L. GordonBoard Member

Similar to MBX Biosciences

Merganser BiotechNewtown Square, PA, USMedicineest. 2011Merganser BiotechNewtown Square, PA, US · est. 2011

Merganser Biotech Inc., a medicine development company, innovates therapeutic treatments for human diseases.

Series B · $28M30

Petri BioLos Angeles, CA, USTherapeuticsest. 2019Petri BioLos Angeles, CA, US · est. 2019

Petri Bio: A biotech firm innovating gut microbe-based therapeutics.

Xeno BiosciencesCambridge, MA, USBiopharmaceuticals, Therapeuticsest. 2015Xeno BiosciencesCambridge, MA, US · est. 2015

Xeno Biosciences, a biopharmaceutical pioneer, develops novel therapeutics for metabolic diseases.

Empire BiotechnologiesSan Francisco, CA, USTherapeuticsest. 2013Empire BiotechnologiesSan Francisco, CA, US · est. 2013

Empire Biotechnologies: Innovating therapies for unmet medical needs, focusing on malabsorption diseases.

Pre-Seed · $1.1M1

Ed Mathers's Similar Executives & Operators

Jay Geoffrey WacherBoard Member · Bukalapak

Soemantri BrodjonegoroBoard Member · Bukalapak

Lau Eng BoonBoard Member · Bukalapak

WILL WEI CHENGBoard Member · DiDi

Dhirubhai H. AmbaniBoard Member · Reliance Retail

Mason YeoBoard Member · Kakao

JaeHong ChoiBoard Member · Kakao

Yun SeokBoard Member · Kakao

People Similar to Ed Mathers

Ed AndersonFounder · North Bridge Venture Partners

Steven ShaneBoard Member · SAIC

Joe LonsdaleCo-Founder · Anduin

Beth LoughneyCo-Founder · Boon AI

Matthew DayBoard Member · EquityMetrix

Benjamin BoyerBoard Member · PlanGrid